IS1682B - Aðferð til framleiðslu pyrrol afleiða og milliefni til notkunar við framleiðsluna - Google Patents

Aðferð til framleiðslu pyrrol afleiða og milliefni til notkunar við framleiðsluna

Info

Publication number
IS1682B
IS1682B IS3741A IS3741A IS1682B IS 1682 B IS1682 B IS 1682B IS 3741 A IS3741 A IS 3741A IS 3741 A IS3741 A IS 3741A IS 1682 B IS1682 B IS 1682B
Authority
IS
Iceland
Prior art keywords
stands
bond
sum
together form
production
Prior art date
Application number
IS3741A
Other languages
English (en)
Other versions
IS3741A7 (is
Inventor
David Davis Peter
Huw Hill Christopher
Lawton Geoffrey
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017269A external-priority patent/GB9017269D0/en
Priority claimed from GB919109959A external-priority patent/GB9109959D0/en
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of IS3741A7 publication Critical patent/IS3741A7/is
Publication of IS1682B publication Critical patent/IS1682B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS3741A 1990-08-07 1991-08-02 Aðferð til framleiðslu pyrrol afleiða og milliefni til notkunar við framleiðsluna IS1682B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909017269A GB9017269D0 (en) 1990-08-07 1990-08-07 Substituted pyrroles
GB919109959A GB9109959D0 (en) 1991-05-08 1991-05-08 Substituted pyrroles

Publications (2)

Publication Number Publication Date
IS3741A7 IS3741A7 (is) 1992-02-08
IS1682B true IS1682B (is) 1998-02-24

Family

ID=26297468

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3741A IS1682B (is) 1990-08-07 1991-08-02 Aðferð til framleiðslu pyrrol afleiða og milliefni til notkunar við framleiðsluna

Country Status (26)

Country Link
EP (1) EP0470490B1 (is)
JP (1) JPH0780880B2 (is)
KR (1) KR100233964B1 (is)
AT (1) ATE179710T1 (is)
AU (1) AU649699B2 (is)
CA (1) CA2046801C (is)
CZ (1) CZ280359B6 (is)
DE (1) DE69131190T2 (is)
DK (1) DK0470490T3 (is)
DZ (1) DZ1521A1 (is)
ES (1) ES2132076T3 (is)
FI (1) FI95909C (is)
GR (1) GR3030677T3 (is)
HU (1) HU210547B (is)
IE (1) IE912787A1 (is)
IL (1) IL99064A (is)
IS (1) IS1682B (is)
MC (1) MC2279A1 (is)
MY (1) MY106400A (is)
NO (1) NO179143C (is)
NZ (1) NZ239216A (is)
PT (1) PT98583B (is)
RO (1) RO112724B1 (is)
RU (1) RU2075474C1 (is)
SK (1) SK279566B6 (is)
UA (1) UA27100A1 (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (ja) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド 抗ウイルス活性を有するインドール誘導体
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
HUT69164A (en) * 1993-12-07 1995-08-28 Lilly Co Eli Improved process for producing bis-indolyl-maleimide derivatives
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
SG63570A1 (en) * 1993-12-07 1999-03-30 Lilly Co Eli Protein kinase c inhibitors
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US6025897A (en) 1993-12-21 2000-02-15 3M Innovative Properties Co. Display with reflective polarizer and randomizing cavity
US6804058B1 (en) 1993-12-21 2004-10-12 3M Innovative Properties Company Electroluminescent light source and display incorporating same
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5554608A (en) * 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
WO1998018466A2 (en) * 1996-10-31 1998-05-07 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
TR199902923T2 (xx) * 1997-06-02 2000-11-21 Janssen Pharmaceutica N.V. Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.
DE19802708A1 (de) * 1998-01-24 1999-07-29 Hoechst Marion Roussel De Gmbh Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren
JP2002520315A (ja) 1998-07-08 2002-07-09 ハーバー ブランチ オーシャノグラフィック インスティテューション インク. ビスインドール誘導体および抗炎症剤としてのそれらの使用
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
FR2796274B1 (fr) * 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
MXPA06001524A (es) 2003-08-08 2006-05-15 Novartis Ag Combinaciones que comprenden estaurosporinas.
US20070232658A1 (en) * 2004-04-08 2007-10-04 Jurgen Wagner Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
RU2413511C2 (ru) * 2004-04-08 2011-03-10 Новартис Аг Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата
FR2870538B1 (fr) * 2004-05-19 2006-07-14 Servier Lab Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3169337A1 (en) 2014-07-17 2017-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem

Also Published As

Publication number Publication date
NZ239216A (en) 1994-05-26
IS3741A7 (is) 1992-02-08
SK279566B6 (sk) 1999-01-11
NO179143B (no) 1996-05-06
ES2132076T3 (es) 1999-08-16
JPH04230686A (ja) 1992-08-19
JPH0780880B2 (ja) 1995-08-30
EP0470490A1 (en) 1992-02-12
MC2279A1 (fr) 1993-06-23
RU2075474C1 (ru) 1997-03-20
MY106400A (en) 1995-05-30
AU649699B2 (en) 1994-06-02
EP0470490B1 (en) 1999-05-06
IL99064A0 (en) 1992-07-15
NO179143C (no) 1996-08-14
AU8167291A (en) 1992-02-13
KR920004380A (ko) 1992-03-27
HU210547B (en) 1995-05-29
CS243591A3 (en) 1992-02-19
IL99064A (en) 1995-08-31
DE69131190T2 (de) 1999-11-04
HU912589D0 (en) 1992-01-28
HUT61542A (en) 1993-01-28
CA2046801C (en) 2002-02-26
PT98583B (pt) 1999-03-31
FI913754A0 (fi) 1991-08-07
FI913754L (fi) 1992-02-08
RO112724B1 (ro) 1997-12-30
KR100233964B1 (ko) 1999-12-15
IE912787A1 (en) 1992-02-12
FI95909C (fi) 1996-04-10
PT98583A (pt) 1992-06-30
DK0470490T3 (da) 1999-11-01
UA27100A1 (uk) 2000-02-28
NO913051L (no) 1992-02-10
ATE179710T1 (de) 1999-05-15
FI95909B (fi) 1995-12-29
DE69131190D1 (de) 1999-06-10
NO913051D0 (no) 1991-08-06
GR3030677T3 (en) 1999-11-30
DZ1521A1 (fr) 2004-09-13
CZ280359B6 (cs) 1995-12-13
CA2046801A1 (en) 1992-02-08

Similar Documents

Publication Publication Date Title
IS3741A7 (is) Aðferð til framleiðslu pyrrol afleiða og milliefni til notkunar við framleiðsluna
HU9200278D0 (en) 2,3,6.-substituted kinazolinon derivatives with angiotenzyn ii receptor blocing effect
TW249234B (is)
ATE237631T1 (de) Neue thrombininhibitoren, ihre herstellung und verwendung
AU1163492A (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analog
FI103971B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten pyrrolo- ja pyrido[2,3-d]pyrimidinonijohdannaisten valmistamiseksi
FI935529A0 (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
HUT71492A (en) Substituted pyrrol derivatives
ATE83480T1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
AU621634B2 (en) Glycerin derivative and its pharmacological use
DE3880304D1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
EP0802179A4 (en) DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER
NO951812L (no) Pyrrolderivater, deres fremstilling og anvendelse
SG47459A1 (en) Process for preparing enantiomerically pure imidazo(4,5,1)(1,4)benzodiazepin-2(1H)-thiones
ATE124398T1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung.
ATE164574T1 (de) Verfahren zur herstellung von aminobutene- derivate
AU2013888A (en) Uricosuric composition
DE59208712D1 (de) Neue cytarabin-derivate, ihre herstellung und verwendung